Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BF.31NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.4.6NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.13NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.3.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.10.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.56NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.29NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.2.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.51NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BA.2.3.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
XATNSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.18NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-1549.93US
BF.5.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BN.1.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BN.1.3.7NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.25NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BA.5.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-820.864US
BF.7.4.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-630.996US
BN.1.3.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26313.4US
BL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-25183.9US
BA.5.2.47NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BE.4NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.1.24NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BA.5.1.16NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.26NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4388.79US
BF.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BA.5.2.22NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BF.38NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
DK.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
BQ.1.11.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-23154.8US
BA.5.2.63NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FM.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GA.4.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GK.1.10.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.10NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GN.1.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.13.3.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
GW.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.424NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.5NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
AF.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.177.89NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
M.2NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.333NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.429NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.463NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used